Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368921 | 0.84 | DPP4 (0.46) | CYP1A2LSSDPP4BACE1BCHE | |
| SCHEMBL14368895 | 0.84 | DPP4 (0.46) | CYP1A2LSSDPP4BACE1BCHE | |
| Hydrochloric Acid SCHEMBL27778302 | 0.83 | DPP4 (0.45) | CYP1A2LSSDPP4BACE1 | |
| Hydrochloric Acid SCHEMBL4435677 | 0.83 | DPP4 (0.45) | CYP1A2LSSDPP4BACE1 | |
| SCHEMBL13560155 | 0.83 | CYP1A2 (0.57) | CYP1A2LSSDPP4ACHEBACE1 | |
| SCHEMBL14368920 | 0.82 | CYP1A2 (0.41) | CYP1A2LSSCCR3 | |
| SCHEMBL14368869 | 0.80 | DPP4 (0.42) | CYP1A2LSSDPP4BACE1CHRM5 | |
| SCHEMBL14368876 | 0.80 | DPP4 (0.42) | CYP1A2LSSDPP4BACE1CHRM5 | |
| SCHEMBL14368858 | 0.80 | DPP4 (0.42) | CYP1A2LSSDPP4BACE1CHRM5 | |
| SCHEMBL14368879 | 0.79 | LSS (0.42) | CYP1A2LSSDPP4BACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CYP1A2 285/4885LSS 1418/4885DPP4 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.